TP53 and mucoepidermoid carcinoma: Given that patients with mucoepidermoid carcinoma express high levels of MDM2 protein, using the MI-773 inhibitor could be a good strategy to reduce CSCs by the inhibition of the MDM2–p53 interaction [76].